Methods for the treatment of B cell-mediated inflammatory diseases
View Patent ↗Methods for treating diseases associated with chemokine (C-X-C motif) ligand 13 (CXCL13) expression, including certain autoimmune and inflammatory diseases such as Sjogren's syndrome are provided herein. The methods comprise administering to a subject in need thereof an effective amount of an agent that inhibits CXCL13 activity. According to aspects of the invention illustrated herein, there is provided a method of treating, preventing, or reducing the exacerbation of a B-cell-mediated inflammatory condition in a subject, including administering to a subject an effective amount of an isolated binding molecule which specifically binds to CXCL13, wherein said molecule prevents or inhibits CXCL13 activity.
1. A method for treating Sjogren's syndrome in a subject, comprising administering to a subject with Sjogren's syndrome an effective amount of an antibody or antigen-binding fragment thereof that specifically binds chemokine (C-X-C motif) ligand 13 (CXCL13) and inhibits CXCL13 activity, wherein said antibody or antigen-binding fragment thereof has a heavy chain and a light chain selected from the group consisting of:
a) a heavy chain comprising three complementarity-determining regions (CDRs) of SEQ ID NO: 14 and a light chain comprising three CDRs of SEQ ID NO: 19;
b) a heavy chain comprising three CDRs of SEQ ID NO: 14 and a light chain comprising three CDRs of SEQ ID NO: 21; and
c) a heavy chain comprising three CDRs of SEQ ID NO: 10 and a light chain comprising three CDRs of SEQ ID NO: 15.
2. The method of claim 1 , wherein said antibody is chimeric, human, or humanized.
3. The method of claim 1 , wherein said antibody or antigen-binding fragment that specifically binds to CXCL13 comprises a variable heavy (VH) domain and a variable light (VL) domain having amino acid sequences identical to VH and VL sequences selected from the group consisting of:
a) SEQ ID NO: 14 and SEQ ID NO: 19, respectively;
b) SEQ ID NO: 14 and SEQ ID NO: 21, respectively; and
c) SEQ ID NO: 10 and SEQ ID NO: 15, respectively.
4. The method of claim 1 , wherein said antibody or antigen-binding fragment that specifically binds to CXCL13 comprises a variable heavy (VH) domain having the sequence set forth in SEQ ID NO: 14 and a variable light (VL) domain having the sequence set forth in SEQ ID NO: 19.
5. The method of claim 1 , wherein said antibody is an IgG1 kappa antibody.
6. The method of claim 5 , wherein said antibody comprises a human IgG1 constant region and a human kappa constant region.
7. The method of claim 1 , wherein said antigen-binding fragment is selected from the group consisting of a Fab, a F(ab′) 2 , a Fv, and a scFv.
8. The method of claim 1 , wherein said antibody or antigen-binding fragment thereof inhibits CXCL13 interaction with a CXCL13 receptor.
9. The method of claim 8 , wherein said CXCL13 receptor is C-X-C chemokine receptor 5 (CXCR5) or C-X-C chemokine receptor 3 (CXCR3).
10. The method of claim 1 , wherein said antibody or antigen-binding fragment thereof is administered with a pharmaceutically acceptable carrier.
11. The method of claim 1 , wherein said subject is an animal.
12. The method of claim 11 , wherein said animal is a mammal.
13. The method of claim 12 , wherein said mammal is a human.
14. The method of claim 1 , wherein said antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising a CDR1 having the sequence set forth in SEQ ID NO: 11, a CDR2 having the sequence set forth in SEQ ID NO: 12, and a CDR3 having the sequence set forth in SEQ ID NO: 13; and a variable light (VL) domain comprising a CDR1 having the sequence set forth in SEQ ID NO: 20, a CDR2 having the sequence set forth in SEQ ID NO: 17, and a CDR3 having the sequence set forth in SEQ ID NO: 18.
15. The method of claim 1 , wherein said antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising a CDR1 having the sequence set forth in SEQ ID NO: 11, a CDR2 having the sequence set forth in SEQ ID NO: 12, and a CDR3 having the sequence set forth in SEQ ID NO: 13; and a variable light (VL) domain comprising a CDR1 having the sequence set forth in SEQ ID NO: 16, a CDR2 having the sequence set forth in SEQ ID NO: 17, and a CDR3 having the sequence set forth in SEQ ID NO: 18.